Endocrinology News

Access Pharmaceuticals Initiates Program Applying Cobalamin Platform To SiRNA Drug Delivery

Thu, 18 Feb 2010 10:01:11 GMT

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies.

��

Protalix Presents Additional Phase III Data For Taliglucerase Alfa At The WORLD Symposium

Thu, 18 Feb 2010 05:04:41 GMT

Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa.

��

Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study Of Amigal TM For Fabry Disease

Thu, 18 Feb 2010 03:38:09 GMT

Amicus Therapeutics (Nasdaq: FOLD) announced additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™

��

Shire Presents Positive Efficacy And Safety Data For Velaglucerase Alfa In Treatment Of Naive Patients With Type 1 Gaucher Disease

Thu, 18 Feb 2010 02:31:00 GMT

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease.

��

TAU Finds The Female Hormone May Protect Women From Psychosis

Tue, 16 Feb 2010 10:30:09 GMT

Many American women are prescribed estrogen to combat the negative effects of menopause, such as bone loss and mood swings. Now, new evidence from a Tel Aviv University study suggests that hormone replacement therapy might also protect them - and younger women - from schizophrenia as well.

��

Stress Hormone Key To Alcohol Dependence

Tue, 16 Feb 2010 09:28:03 GMT

A team of scientists from The Scripps Research Institute has found that a specific stress hormone, the corticotropin-releasing factor (CRF), is key to the development and maintenance of alcohol dependence in animal models.

��

The Endocrine Society Recommends Against Changes In Blood Sugar Control Goals In Response To Study On A1C Levels And Mortality Published In Lancet

Tue, 16 Feb 2010 08:24:03 GMT

A study published this week in Lancet suggests that low A1C levels may be just as dangerous as high A1C levels in diabetes patients with respect to mortality and cardiovascular outcomes.

��

Childhood Obesity May Contribute To Later Onset Of Puberty For Boys

Tue, 16 Feb 2010 07:16:04 GMT

Increasing rates of obese and overweight children in the United States may be contributing to a later onset of puberty in boys, say researchers at the University of Michigan.

��

Fat Behaves Differently In Patients With Polycistic Ovary Syndrome

Tue, 16 Feb 2010 05:54:08 GMT

Fat tissue in women with Polycystic Ovary Syndrome produces an inadequate amount of the hormone that regulates how fats and glucose are processed, promoting increased insulin resistance and inflammation, glucose intolerance, and greater risk of diabetes and heart disease, according to a study conducted at the Center for Androgen-Related Research and Discovery at Cedars-Sinai Medical Center.

��

Low Forms Of Cyclin E Reduce Breast Cancer Drug's Effectiveness

Sun, 14 Feb 2010 09:10:04 GMT

Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from The University of Texas M.

��